Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01226693 | A Study In Healthy Volunteers To Assess The Safety, Tolerability, And Relative Oral Bioavailability Of Three Formulations Of PH-797804 | PHASE1 | COMPLETED | 18 | — | — | Nov 1, 2010 | Mar 1, 2011 | Mar 10, 2011 | 1 | Singapore |
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | - |
| Sequence 2 | EXPERIMENTAL | - |
| Sequence 3 | EXPERIMENTAL | - |
| Sequence 4 | EXPERIMENTAL | - |
| Sequence 5 | EXPERIMENTAL | oral, 6mg, single dose |
| Sequence 6 | EXPERIMENTAL | oral, 6mg, single dose |
| Name | Type | Description |
|---|---|---|
| PH-797804 material sparing tablet | DRUG | oral, 6mg, single dose |
| PH-797804 Phase2b/3 with sodium lauryl sulphate | DRUG | oral, 6mg, single dose |
| PH-797804 Phase2b/3 without sodium lauryl sulphate | DRUG | oral, 6mg, single dose |
Inclusion Criteria: * Healthy male and female subjects of non-childbearing potential between the ages of 21 and 55. * No evidence of active or latent TB. * An informed consent document signed and dated by the subject. Exclusion Criteria: * Evidence, including abnormal clinical laboratory paramete...